NHL Clinical Trial
Official title:
A Multicenter Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of BN102 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-cell Non-Hodgkin's Lymphoma (NHL)
This is a Multicenter Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of BN102 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-cell Non-Hodgkin's Lymphoma (NHL)
The study is divided into 2 phases. Phase1 dose escalation part will enroll 17-36 patients to evaluate safety and tolerance of BN102 in patients with relapsed/refractory (R/R) CLL/SLL and B-NHL to determine maximum tolerated dose and recommended phase2 dose(RP2D). Phase 2 expansion part will enroll 72-138 patients and be conducted at the selected dose level to further evaluate the safety and tolerability of BN102,as well as preliminary efficacy in specific subtypes of lymphoma. Patients will be allocated into 6 lymphoma subgroup cohorts depends on whether their previous treatment with or without BTK inhibitors. - Cohort 1: patients with mantle cell lymphoma (MCL) previously treated with BTK inhibitors - Cohort 2: patients with MCL who have not previously received a BTK inhibitor - Cohort 3: patients with CLL/SLL who have received prior BTK inhibitors - Cohort 4: patients with CLL/SLL who have not received prior BTK inhibitors - Cohort 5: other B-NHL patients who have received prior BTK inhibitors - Cohort 6: other B-NHL patients who have not received prior BTK inhibitors Patients will receive orally administrated BN102 twice daily under fasting status. Study drug will be administered in 28-day cycles until disease progression or unacceptable toxicity, death, ICF withdraw ect. Subjects may receive study drug in the inpatient or outpatient setting. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04555811 -
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
|
Phase 1 | |
| Completed |
NCT00333190 -
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation
|
N/A | |
| Recruiting |
NCT03535753 -
Safety and Efficacy Evaluation of Decitabine With R-GDP
|
Phase 1 | |
| Recruiting |
NCT06119685 -
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
|
Phase 1/Phase 2 | |
| Completed |
NCT00513175 -
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia
|
N/A | |
| Recruiting |
NCT05641428 -
Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL
|
Phase 2 | |
| Recruiting |
NCT05879744 -
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
|
Phase 1 | |
| Completed |
NCT00342121 -
Influence of Corn Farming on the Immune System
|
||
| Withdrawn |
NCT01101581 -
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04139252 -
A National Study for Blood Based Response Monitoring of B-cell Lymphoma Patients
|
||
| Recruiting |
NCT04440436 -
Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients
|
Phase 1/Phase 2 | |
| Terminated |
NCT04840784 -
First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML
|
Phase 1 | |
| Recruiting |
NCT05665062 -
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
|
Phase 1 | |
| Terminated |
NCT02702492 -
PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)
|
Phase 1 | |
| Completed |
NCT03527147 -
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)
|
Phase 1 | |
| Terminated |
NCT00814983 -
Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02847949 -
A Study of IGN002 for Refractory NHL
|
Phase 1 | |
| Completed |
NCT00891592 -
Umbilical Cord Blood Transplant for Hematological Malignancies
|
Phase 1 | |
| Completed |
NCT00546793 -
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03739502 -
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
|
Phase 2 |